BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Celltrion to begin clinical trial soon with candidate for antibody treatment

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : July 9, 2020, 10:53 | Updated : July 9, 2020, 10:53
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]


SEOUL -- Celltrion, a South Korean bio firm involved in a project to find the treatment of COVID-19 patients, will begin clinical trials this month with the candidate for antibody treatment that was found to be more effective in neutralizing the mutant strain of the new coronavirus.

Celltrion said it would begin clinical trials on July 16. Its goal is to mass-produce therapeutic antibodies in the first half of next year. The Korea National Institute of Health, a state research body, has selected Celltrion as a cooperation partner to develop vaccines and medicine. The company has verified selected candidates for antibody treatment.

In an evaluation test conducted by the Korea Centers for Disease Control and Prevention (KCDC), Celltrion's antibody treatment was found to be more effective in neutralizing the mutated strain of the SARS-CoV-2 coronavirus that was identified in genetic data of samples collected from patients from abroad.

Based on the outcome of gene sequencing released on July 6, KCDC director Jeong Eun-kyeong attributed the recent spread of COVID-19 in South Korea to the genetic strain which has been widely reported in Europe and other regions. She said that the mutant strain has higher propagation than the virus that hit South Korea earlier.


 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Celltrions antibody COVID-19 treatment wins approval from S. Korean state watchdog.
    Celltrion's antibody COVID-19 treatment wins approval from S…
  • .  Celltrion checks antibody treatments effect of COVID-19 infection prevention    .
    Celltrion checks antibody treatment's effect of COVID-19 i…
  • .GC Pharmas immunoglobulin drug administered to patients in second-stage clinical study .
    GC Pharma's immunoglobulin drug administered to patients in …

Real Time Photo News

  • .BLACKPINK member Rosé to release solo album in March.

    BLACKPINK member Rosé to release solo album in March

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

Latest News

more+

  • Hyundai auto group forges hydrogen alliance with SK Group
  • Scuba diving in Cebu cited as most viewed content in LG Uplus VR platform
  • SKT uses VR platform to hold non-face-to-face entrance ceremony for university freshmen
  • Hyundai auto group holds groundbreaking ceremony for fuel cell plant in China
  • BLACKPINK member Rosé to release solo album in March
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view